Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MME | P08473 | 2/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 4/20 | 0.41 |
| ▸ | APP | P05067 | 3/20 | 0.41 |
| ▸ | CNR1 | P21554 | 3/20 | 0.40 |
| ▸ | CTSS | P25774 | 3/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22901858 | 1.00 | ATM (0.48) | ATMPPARGPPARACACNA1BGAA | |
| SCHEMBL20747204 | 0.87 | ATM (0.47) | ATMPPARGPPARACACNA1BGAA | |
| SCHEMBL22903798 | 0.87 | ATM (0.47) | ATMPPARGPPARACACNA1BGAA | |
| SCHEMBL740780 | 0.85 | MME (0.56) | ATMPPARGPPARACACNA1BGAA | |
| SCHEMBL5966601 | 0.85 | MME (0.56) | ATMPPARGPPARACACNA1BGAA | |
| SCHEMBL740779 | 0.85 | MME (0.56) | ATMPPARGPPARACACNA1BGAA | |
| SCHEMBL28556360 | 0.84 | ATM (0.51) | ATMPPARGPPARACACNA1BGAA | |
| SCHEMBL20415719 | 0.84 | ATM (0.51) | ATMPPARGPPARACACNA1BGAA | |
| SCHEMBL7019352 | 0.82 | ATM (0.54) | ATMPPARGPPARACACNA1BGAA | |
| SCHEMBL18589398 | 0.82 | ATM (0.54) | ATMPPARGPPARACACNA1BGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12325701-B2 | YKL-40 inhibitors and their therapeutic | MOLECURE S.A. (PL) | 2025-06-10 | — | — | US | disclosed |
| US-20230278996-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | MOLECURE S.A. (PL) | 2023-09-07 | — | — | US | disclosed |
| US-20230278996-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | MOLECURE S.A. (PL) | 2023-09-07 | — | — | US | disclosed |
| US-11638707-B2 | Substituted amino triazoles useful as chitinase inhibitors | MOLECURE S.A. (PL) | 2023-05-02 | — | — | US | disclosed |
| EP-3999500-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS CHITINASE INHIBITORS | OncoArendi Therapeutics S.A. (PL) | 2022-05-25 | — | — | EP | disclosed |
| US-20190345137-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | GALAPAGOS NV (BE) | 2019-11-14 | — | — | US | disclosed |
| US-10208020-B2 | Substituted amino triazoles useful as human chitinase inhibitors | Oncoarendi Therapeutics S.A. (PL) | 2019-02-19 | — | — | US | disclosed |
| US-9944624-B2 | Substituted amino triazoles useful as human chitinase inhibitors | Oncoarendi Therapeutics S.A. (PL) | 2018-04-17 | — | — | US | disclosed |
| US-9944624-B2 | Substituted amino triazoles useful as human chitinase inhibitors | Oncoarendi Therapeutics S.A. (PL) | 2018-04-17 | — | — | US | disclosed |
| US-20170066743-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | GALAPAGOS NV (BE) | 2017-03-09 | — | — | US | disclosed |
| US-20170066743-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | GALAPAGOS NV (BE) | 2017-03-09 | — | — | US | disclosed |
| WO-2017037670-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | OncoArendi Therapeutics Sp. z o.o. (PL) | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190345137-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | CHIA, CHIT1, AADAC | ATM 707/4885PPARG 3255/4885PPARA 3785/4885 |
| US-20230278996-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | CHI3L1, CHI3L2, CHIA | ATM 2618/4885PPARG 4776/4885PPARA 4708/4885 |
| US-12325701-B2 | YKL-40 inhibitors and their therapeutic | CHI3L1, CHI3L2, CHIA | ATM 2548/4885PPARG 4735/4885PPARA 4651/4885 |
| US-10208020-B2 | Substituted amino triazoles useful as human chitinase inhibitors | CHIA, CHIT1, AADAC | ATM 707/4885PPARG 3255/4885PPARA 3785/4885 |
| US-20170066743-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | CHIA, CHIT1, AADAC | ATM 707/4885PPARG 3255/4885PPARA 3785/4885 |
| US-11638707-B2 | Substituted amino triazoles useful as chitinase inhibitors | CHIT1, CHIA, CHI3L1 | ATM 543/4885PPARG 3658/4885PPARA 4350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.